Tag Archives: Chronic

FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML)

FDA Approves Inqovi (decitabine and cedazuridine) for Myelodysplastic Syndromes (MDS) including Chronic Myelomonocytic Leukemia (CMML) Print this page Pleasanton, CA, Princeton, NJ, and Tokyo, Japan, July 7, 2020. Astex Pharmaceuticals, Inc.; Taiho Oncology, Inc.; and Otsuka Pharmaceutical Co., Ltd. today announce that the U.S. Food and Drug Administration (FDA) and Health Canada have approved Inqovi… Read More »

Ofev Approved for Chronic Fibrosing ILDs With Progressive Phenotype

TUESDAY, March 10, 2020 — Ofev (nintedanib) oral capsules have received the first approval for the treatment of patients with chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, the U.S. Food and Drug Administration announced Monday. Ofev, a multitargeted tyrosine kinase inhibitor, was approved in 2014 to treat idiopathic pulmonary fibrosis and to… Read More »

Young woman who Instagrams her chronic acne on her daily battle – South China Morning Post

Emily Keel, 24, is a personal trainer, mindful of exercise and her diet. She has long, thick dark hair and enormous green eyes. She has great teeth and a fabulous smile. But she also has acne, which frequently makes her unhappy. Snapchat dysmorphia: depression, cosmetic surgery and addiction Yet, in a courageous attempt to support… Read More »

FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC)

FDA Approves Motegrity (prucalopride) for Adults with Chronic Idiopathic Constipation (CIC) Print this page Cambridge, Mass. – December 17, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) has announced that the U.S. Food and Drug Administration (FDA) has approved Motegrity™ (prucalopride), a once-daily, oral treatment option for adults with Chronic Idiopathic Constipation (CIC).1 Motegrity, a… Read More »